<DOC>
	<DOC>NCT02161718</DOC>
	<brief_summary>This double-blind, randomized study will evaluate the efficacy, safety and tolerability of ALKS 3831 in subjects with schizophrenia and alcohol use disorder (AUD).</brief_summary>
	<brief_title>A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Has a BMI between 18.0 and 40.0 kg/m2, inclusive Has a diagnosis of schizophrenia Has a diagnosis of alcohol use disorder (AUD) Has experienced an acute exacerbation of schizophrenia within the past 6 months Additional criteria may apply Is pregnant or breastfeeding Had first lifetime psychotic episode less than 1 year before screening or has experienced only a single lifetime psychotic episode Has a known or suspected intolerance, allergy, or hypersensitivity to olanzapine Has current or pending legal charges with the potential for incarceration Has a positive drug screen for opiates Additional criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Alcohol Use Disorder</keyword>
	<keyword>ALKS 3831</keyword>
</DOC>